Just as Humira revolutionised treatment, Samsung Bioepis and Organon’s SB5 offers promise in the realm of biosimilars.Samsung Bioepis Co Ltd (Samsung Bioepis) and Organon & Co (Organon) announced on August 1 their latest clinical trial results evaluating SB5, a biosimilar of the reference tumour necrosis factor (TNF) blocker Humira (adalimumab), approved by the FDA under […]
